Health AI Central
Share:
Peer-Reviewed Publication
J Neuroinflammation2024;21(1):53.February 21, 2024Journal Article

Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson's disease.

Jae-Bong Kim1,2,3, Yujeong Kim4, Soo-Jeong Kim2, Tae-Young Ha1,2,5, Dong-Kyu Kim2, Dong Won Kim4, Minyoung So6, Seung Ho Kim2,7, Hyun Goo Woo2,7, Dukyong Yoon8, Sang Myun Park9,10,11
1Department of Pharmacology, Ajou University School of Medicine, 164, Worldcup-Ro, Yeongtong-Gu, Suwon, 16499, Korea.
2Center for Convergence Research of Neurological Disorders, Ajou University School of Medicine, Suwon, Korea.
3Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University School of Medicine, Suwon, Korea.
4Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.
5Neuroscience Research Institute, Gachon University, Incheon, Korea.
6Standigm Inc., Seoul, Korea.
7Department of Physiology, Ajou University School of Medicine, Suwon, Korea.
8Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea. dukyong.yoon@yonsei.ac.kr.
9Department of Pharmacology, Ajou University School of Medicine, 164, Worldcup-Ro, Yeongtong-Gu, Suwon, 16499, Korea. sangmyun@ajou.ac.kr.
10Center for Convergence Research of Neurological Disorders, Ajou University School of Medicine, Suwon, Korea. sangmyun@ajou.ac.kr.
11Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University School of Medicine, Suwon, Korea. sangmyun@ajou.ac.kr.
PubMed PMC DOI PDF

Abstract

BACKGROUND: Parkinson's disease (PD) is a common and costly progressive neurodegenerative disease of unclear etiology. A disease-modifying approach that can directly stop or slow its progression remains a major unmet need in the treatment of PD. A clinical pharmacology-based drug repositioning strategy is a useful approach for identifying new drugs for PD. METHODS: We analyzed claims data obtaine…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.